title: Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients.
abstract: It has been found that preoperative plasma IGFBP-2 levels correlate with prognosis in glioma patients. The prognostic value of plasma IGFBP-2 after postoperative combined radiotherapy and chemotherapy in glioma patients is unknown. Plasma IGFBP-2 levels in 83 glioblastoma patients after postoperative radiotherapy plus chemotherapy were analyzed using an IGFBP-2 ELISA kit. We found that after standard therapy plasma IGFBP-2 levels significantly correlated with the patient's age (R = 0.738, P<0.001) and Karnofsky performance status (KPS, R =  -0.633, P<0.05). Cox proportional hazards models were used to calculate hazard ratios (HRs) of death according to plasma IGFBP-2 levels adjusted for patient clinical characteristics. Plasma IGFBP-2 levels significantly correlated with overall survival in glioblastoma patients (multivariate HR = 1.035; 95% CI, 1.024-1.047; P<0.001). The effect of plasma IGFBP-2 levels on survival seemed to differ according to patients' age. Among patients older than 60, high plasma IGFBP-2 levels were associated with a significant increase in overall mortality (HR = 1.097; 95% CI, 1.055-1.140; P<0.001). In contrast, plasma IGFBP-2 levels conferred no significant effect on mortality among patients younger than 60. Elevated plasma IGFBP-2 levels after combined postoperative radiotherapy and chemotherapy in elderly glioblastoma patients correlate with poor KPS score and predicts poor prognosis.
authors.affiliation: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Han
authors.affiliation: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
authors.forename: Lingxuan
authors.initials: L
authors.lastname: Meng
authors.affiliation: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Han
authors.affiliation: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
authors.forename: Yunjie
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.
authors.forename: Anhua
authors.initials: A
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D005260:Female; D005909:Glioblastoma / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000097:blood*; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C577903:IGFBP2 protein, human; D018971:Insulin-Like Growth Factor Binding Protein 2